

product announcement

Influenza, Corona, RS-Virus? Fast response in only one PCR run with ViroQ SARS-FluA/B-RSV



Lich, October 23th 2020 – "Normal" flu, RSV infection or CORONA? This is a question that preoccupies patients and healthcare staff in autumn and winter equally. The newly developed PCR rapid test from BAG Diagnostics provides a quick

answer. ViroQ SARS-FluA/B-RSV detects in just one PCR run whether the samples present contain SARS-CoV-2, RS, influenza A or B viruses. In addition, as with the pure corona test ViroQ SARS-CoV-2, the real-time kit indicates whether sufficient cell material for valid test results is contained in the samples from throat and nose swabs.

Autumn is flu season. For many people, uncertainty is increasing as to whether the symptoms present are signs of a "normal flu" or a highly contagious SARS-CoV-2 infection causing COVID-19. BAG Diagnostics, specialised in the development and distribution of in-vitro diagnostics, has further developed its successful PCR rapid test ViroQ SARS-CoV-2: In just one PCR run, laboratories can reliably detect whether tracheal secretion / sputum samples contain SARS-CoV-2, RS, influenza A or B viruses.

The test also shows whether there is sufficient cell material available for valid test results. Incorrectly reported negative results, which occur in conventional tests due to too little material in the samples taken, can be avoided with the new BAG kit.

Fast and flexible to use

Ready-to-use standard reagents and an optimised one-step PCR run ensure high throughput in laboratories. Test results are available after only 60 minutes.

With ViroQ SARS-FluA/B-RSV, laboratories remain independent of suppliers. The rapid test can be combined with common RNA isolation kits. It is designed for use with commercially available real-time PCR instruments.

"During development, it was also very important to us to create a product that could address the needs of patients, physicians and laboratories alike. So on the one hand, another focus was on delivering fast and reliable results. We succeeded in doing this with an optimised PCR protocol. This saves us a good half hour compared to conventional products. That means at least one more complete PCR run per day. On the other hand, we wanted to create conditions for immediate use - in other words, no binding to a specific hardware or other components," explains Dr. Ingo Meier, Division Manager BAG Diagnostics.

Cost-effective shipping

Diagnostics that require permanent cooling are considerably more expensive in terms of logistics. The new test kit has therefore been designed so that it can be shipped uncooled. This ensures that the quality is not affected by temperature fluctuations.

The test is available immediately. Detailed information: www.bag-diagnostics.com

This text has 2,271 characters including spaces. Further information and a wide variety of images are available in electronic form at kerstin.probst@satzanfang.com. A specimen copy to the agency is requested.

Contact:

BAG Diagnostics GmbH
Dr. Ingo D. Meier
Amtsgerichtsstrasse 1-5
35423 Lich
Fon: +49 6404 / 925-315
E-Mail: i.meier@bag-diagnostics.com

Press contact:

Satzanfang – Kommunikation & PR
Kerstin-Alexandra Probst
Vorderreihe 61
23570 Travemünde/Lübeck
Fon: + 49 45 02/ 76 59-742
E-Mail: kerstin.probst@satzanfang.com

About BAG

BAG Diagnostics GmbH, which is part of BAG Holding, is a traditional family business of the Sachsenberg family, which was founded in 1947 by Gotthard Sachsenberg. Dr. med. Nicolas Sachsenberg is the 3rd generation of the Sachsenberg family to direct the fortunes of BAG. The success story began with development laboratories in the rooms of Solms' castle in Lich, Hesse. Today BAG is a worldwide operating company for health care products for safe medical treatment. It develops, produces and distributes in-vitro diagnostics based on the latest research. As a pharmaceutical contract manufacturer, BAG Health Care is specialized in the production of parenteralia and lyophilisates.